192 related articles for article (PubMed ID: 35512065)
21. Zinc binding groups for histone deacetylase inhibitors.
Zhang L; Zhang J; Jiang Q; Zhang L; Song W
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):714-721. PubMed ID: 29616828
[TBL] [Abstract][Full Text] [Related]
22. Histone deacetylase cytoplasmic trapping by a novel fluorescent HDAC inhibitor.
Kong Y; Jung M; Wang K; Grindrod S; Velena A; Lee SA; Dakshanamurthy S; Yang Y; Miessau M; Zheng C; Dritschilo A; Brown ML
Mol Cancer Ther; 2011 Sep; 10(9):1591-9. PubMed ID: 21697394
[TBL] [Abstract][Full Text] [Related]
23. Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases.
Christianson DW
Acc Chem Res; 2024 Apr; 57(8):1135-1148. PubMed ID: 38530703
[TBL] [Abstract][Full Text] [Related]
24. Differential effects of class I isoform histone deacetylase depletion and enzymatic inhibition by belinostat or valproic acid in HeLa cells.
Dejligbjerg M; Grauslund M; Litman T; Collins L; Qian X; Jeffers M; Lichenstein H; Jensen PB; Sehested M
Mol Cancer; 2008 Sep; 7():70. PubMed ID: 18789133
[TBL] [Abstract][Full Text] [Related]
25. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid.
Zhao L; Chen CN; Hajji N; Oliver E; Cotroneo E; Wharton J; Wang D; Li M; McKinsey TA; Stenmark KR; Wilkins MR
Circulation; 2012 Jul; 126(4):455-67. PubMed ID: 22711276
[TBL] [Abstract][Full Text] [Related]
26. Explorative study on isoform-selective histone deacetylase inhibitors.
Suzuki T
Chem Pharm Bull (Tokyo); 2009 Sep; 57(9):897-906. PubMed ID: 19721249
[TBL] [Abstract][Full Text] [Related]
27. Discovery of the First Irreversible HDAC6 Isoform Selective Inhibitor with Potent Anti-Multiple Myeloma Activity.
Liu F; Liu C; Chai Q; Zhao C; Meng H; Xue X; Yao TP; Zhang Y
J Med Chem; 2023 Jul; 66(14):10080-10091. PubMed ID: 37463038
[TBL] [Abstract][Full Text] [Related]
28. A cyclodextrin-capped histone deacetylase inhibitor.
Amin J; Puglisi A; Clarke J; Milton J; Wang M; Paranal RM; Bradner JE; Spencer J
Bioorg Med Chem Lett; 2013 Jun; 23(11):3346-8. PubMed ID: 23591111
[TBL] [Abstract][Full Text] [Related]
29. Hydroxamic Acid-Based Histone Deacetylase (HDAC) Inhibitors Bearing a Pyrazole Scaffold and a Cinnamoyl Linker.
Zagni C; Citarella A; Oussama M; Rescifina A; Maugeri A; Navarra M; Scala A; Piperno A; Micale N
Int J Mol Sci; 2019 Feb; 20(4):. PubMed ID: 30795625
[TBL] [Abstract][Full Text] [Related]
30. Targeting the epigenome: Screening bioactive compounds that regulate histone deacetylase activity.
Godoy LD; Lucas JE; Bender AJ; Romanick SS; Ferguson BS
Mol Nutr Food Res; 2017 Apr; 61(4):. PubMed ID: 27981795
[TBL] [Abstract][Full Text] [Related]
31. [Design, synthesis, and biological activities of histone deacetylase inhibitors with diketo ester as zinc binding group].
Lu H; Su H; Yang B; You QD
Yao Xue Xue Bao; 2011 Mar; 46(3):293-8. PubMed ID: 21626783
[TBL] [Abstract][Full Text] [Related]
32. Phosphorus containing analogues of SAHA as inhibitors of HDACs.
Pun MD; Wu HH; Olatunji FP; Kesic BN; Peters JW; Berkman CE
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):1315-1319. PubMed ID: 35514164
[TBL] [Abstract][Full Text] [Related]
33. Differential protein acetylation induced by novel histone deacetylase inhibitors.
Glaser KB; Li J; Pease LJ; Staver MJ; Marcotte PA; Guo J; Frey RR; Garland RB; Heyman HR; Wada CK; Vasudevan A; Michaelides MR; Davidsen SK; Curtin ML
Biochem Biophys Res Commun; 2004 Dec; 325(3):683-90. PubMed ID: 15541343
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of class IIa histone deacetylase activity by gallic acid, sulforaphane, TMP269, and panobinostat.
Choi SY; Kee HJ; Jin L; Ryu Y; Sun S; Kim GR; Jeong MH
Biomed Pharmacother; 2018 May; 101():145-154. PubMed ID: 29482060
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of histone deacetylases protects septic mice from lung and splenic apoptosis.
Takebe M; Oishi H; Taguchi K; Aoki Y; Takashina M; Tomita K; Yokoo H; Takano Y; Yamazaki M; Hattori Y
J Surg Res; 2014 Apr; 187(2):559-70. PubMed ID: 24290430
[TBL] [Abstract][Full Text] [Related]
37. Differential regulation of Bdnf expression in cortical neurons by class-selective histone deacetylase inhibitors.
Koppel I; Timmusk T
Neuropharmacology; 2013 Dec; 75():106-15. PubMed ID: 23916482
[TBL] [Abstract][Full Text] [Related]
38. Utilization of tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinone as a cap moiety in design of novel histone deacetylase inhibitors.
Mohamed MFA; Youssif BGM; Shaykoon MSA; Abdelrahman MH; Elsadek BEM; Aboraia AS; Abuo-Rahma GEA
Bioorg Chem; 2019 Oct; 91():103127. PubMed ID: 31374527
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and applications of benzohydroxamic acid-based histone deacetylase inhibitors.
De Vreese R; D'hooghe M
Eur J Med Chem; 2017 Jul; 135():174-195. PubMed ID: 28453994
[TBL] [Abstract][Full Text] [Related]
40. Identification of an epigenetic signature of early mouse liver regeneration that is disrupted by Zn-HDAC inhibition.
Huang J; Schriefer AE; Yang W; Cliften PF; Rudnick DA
Epigenetics; 2014 Nov; 9(11):1521-31. PubMed ID: 25482284
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]